Clinical trial
Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of…
NCT00082667 · Vanderbilt-Ingram Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00082667 |
|---|---|
| Title | Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast |
| Official title | EGFR Pathway Modulation In Patients With Ductal Carcinoma In Situ Of The Breast |
| Lead sponsor | Vanderbilt-Ingram Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Procedure |
| Interventions | gefitinib, Surgery |
| Enrollment | 1 |
| Start date | Oct 1, 2002 |
| Primary completion | Jul 1, 2004 |
| Completion | Jun 1, 2005 |
| First posted | May 19, 2004 |
| Last update posted | Feb 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: